0001209191-16-095842.txt : 20160204
0001209191-16-095842.hdr.sgml : 20160204
20160204185227
ACCESSION NUMBER: 0001209191-16-095842
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160202
FILED AS OF DATE: 20160204
DATE AS OF CHANGE: 20160204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEIDEN JEFFREY M
CENTRAL INDEX KEY: 0001242825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 161389823
MAIL ADDRESS:
STREET 1: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-02-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001242825
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2016-02-02
4
A
0
53817
0.01
A
271719
D
Common Stock
2016-02-03
4
S
0
4200
89.91
D
267519
D
Common Stock
2016-02-03
4
S
0
3700
91.01
D
263819
D
Common Stock
2016-02-03
4
S
0
900
91.96
D
262919
D
Common Stock
2016-02-03
4
S
0
1034
92.87
D
261885
D
Common Stock
440
I
401(k)
Stock Option (Right to Buy)
91.05
2016-02-02
4
A
0
107276
0.00
A
2026-02-01
Common Stock
107276
107276
D
Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27).
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.33).
Open market sales reported on this line occurred at a weighted average price of $91.96 (range $91.40 to $92.37).
Open market sales reported on this line occurred at a weighted average price of $92.87 (range $92.50 to $93.11).
The option vests in 16 quarterly installments from 02/02/2016.
Omar White, Attorney-In-Fact
2016-02-04